Search

Your search keyword '"Zuzana, Motovska"' showing total 118 results

Search Constraints

Start Over You searched for: Author "Zuzana, Motovska" Remove constraint Author: "Zuzana, Motovska"
118 results on '"Zuzana, Motovska"'

Search Results

1. The role of pre-existing left-sided valvular heart disease in the prognosis of patients with acute myocardial infarction

2. Impact of admitting department on the management of acute coronary syndrome after an out of hospital cardiac arrest

4. Trends in outcomes of women with myocardial infarction undergoing primary angioplasty—Analysis of randomized trials

5. A contemporary approach to a young female patient with Loeys-Dietz syndrome and an uncomplicated type B aortic dissection: a case report

6. Laboratory Predictors of Prognosis in Cardiogenic Shock Complicating Acute Myocardial Infarction

7. Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/percutaneous coronary intervention

8. A pilot randomised trial of catheter-directed thrombolysis or standard anticoagulation for patients with intermediate-high risk acute pulmonary embolism

11. Mortality in patients with TIMI 3 flow after PCI in relation to time delay to reperfusion

12. Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction - insights from the IAMI trial

13. Impact of admitting department on the management of acute coronary syndrome after an out of hospital cardiac arrest

15. Care of patients with ST-Elevation MI: an international analysis of Quality Indicators in the Acute Coronary Syndrome (ACS) STEMI Registry of the EURObservational Research Programme (EORP) and ACVC and EAPCI Associations of the European Society of Cardiology (ESC) in 11,462 patients

17. Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study.

18. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction

20. Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel

21. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

22. Modified Strategies for Invasive Management of Acute Coronary Syndrome during the COVID-19 Pandemic

23. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial

25. Clinical outcomes with drug-eluting stents, bare-metal stents, and bioresorbable scaffolds implanted in patients with AMI treated with primary PCI. Data from the Prague-18 trial

26. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

27. The relationship between symptom onset-to-needle time and ischemic outcomes in patients with acute myocardial infarction treated with primary PCI

29. The Effect of Symptom Onset-to-needle time on Ischemic Outcomes in Patients Treated with Primary Angioplasty in the Era of Potent Antiplatelets

30. Relation of lipoprotein(a) levels to incident type 2 diabetes and modification by alirocumab treatment

31. Influenza Vaccination After Myocardial Infarction:A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

32. Relationship between symptom-onset-to-balloon time and outcomes in patients with acute myocardial infarction treated with primary percutaneous coronary intervention

33. The Effect of Diabetes on Prognosis Following Myocardial Infarction Treated with Primary Angioplasty and Potent Antiplatelet Therapy

34. Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study

35. The prognostic significance of periprocedural infarction in the era of potent antithrombotic therapy. The PRAGUE-18 substudy

38. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

39. Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial

40. Clinical and laboratory predictors of Infectious Complications in patients after Out-of-Hospital Cardiac Arrest

41. Association of polymorphisms of platelet receptors GPIa (807C>T), GPVI (13254T>C), and P2Y12 (34C>T and H1/H2 haplotype) with increased risk of periprocedural bleeding in patients undergoing coronary angiography/percutaneous coronary intervention

42. P4786Dual antithrombotic therapy is similarly effective to triple therapy in preventing thrombotic events in patients with atrial fibrillation and acute coronary syndrome

43. 3300MiR-126-3P and MiR-223-3p in Prediction of Thrombotic Risk in Patients with Acute Myocardial Infarction and Primary Angioplasty, The Prague-18 Genetic Sub-study

44. The ESC ACCA EAPCI EORP acute coronary syndrome ST-elevation myocardial infarction registry

45. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention

46. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

47. Stent Thrombosis After ACS-PCI: Does Adherence to Antiplatelet Therapy Involve More Than Its Intensity?

49. 12 months of DAPT after acute coronary syndrome still beats 6 months

50. Antiplatelet efficacy of P2Y12 inhibitors (prasugrel, ticagrelor, clopidogrel) in patients treated with mild therapeutic hypothermia after cardiac arrest due to acute myocardial infarction

Catalog

Books, media, physical & digital resources